- Home
- TNK vs SNDX Comparison
TNK vs SNDX Comparison
Compare TNK & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNK
- SNDX
- Stock Information
- Founded
- TNK 2007
- SNDX 2005
- Country
- TNK Bermuda
- SNDX United States
- Employees
- TNK N/A
- SNDX N/A
- Industry
- TNK Marine Transportation
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- TNK Consumer Discretionary
- SNDX Health Care
- Exchange
- TNK Nasdaq
- SNDX Nasdaq
- Market Cap
- TNK 1.3B
- SNDX 1.2B
- IPO Year
- TNK 2007
- SNDX 2016
- Fundamental
- Price
- TNK $38.28
- SNDX $12.29
- Analyst Decision
- TNK Buy
- SNDX Strong Buy
- Analyst Count
- TNK 3
- SNDX 10
- Target Price
- TNK $62.00
- SNDX $36.20
- AVG Volume (30 Days)
- TNK 354.0K
- SNDX 1.7M
- Earning Date
- TNK 05-08-2025
- SNDX 03-03-2025
- Dividend Yield
- TNK 2.60%
- SNDX N/A
- EPS Growth
- TNK N/A
- SNDX N/A
- EPS
- TNK 11.63
- SNDX N/A
- Revenue
- TNK $1,229,336,000.00
- SNDX $23,680,000.00
- Revenue This Year
- TNK N/A
- SNDX $274.86
- Revenue Next Year
- TNK N/A
- SNDX $130.47
- P/E Ratio
- TNK $3.33
- SNDX N/A
- Revenue Growth
- TNK N/A
- SNDX N/A
- 52 Week Low
- TNK $35.23
- SNDX $12.06
- 52 Week High
- TNK $74.20
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- TNK 47.08
- SNDX 37.03
- Support Level
- TNK $37.47
- SNDX $12.70
- Resistance Level
- TNK $39.01
- SNDX $13.80
- Average True Range (ATR)
- TNK 1.23
- SNDX 0.66
- MACD
- TNK 0.15
- SNDX -0.03
- Stochastic Oscillator
- TNK 60.65
- SNDX 7.60
About TNK Teekay Tankers Ltd.
Teekay Tankers Ltd is a provider of marine services to the global oil and natural gas industries and an operator of medium-sized oil tankers. The company operates in two segments: tanker and ship-to-ship transfer. The vast majority of its revenue comes from the tanker segment, which consists of crude oil and product tankers for different contracts.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.